357263-43-5

Usage

Uses

Used in Pharmaceutical Industry:
5-chloro-7-methyl-1H-pyrrolo[3,2-b]pyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to contribute to the development of new drug candidates. Its potential as an inhibitor of protein kinases makes it a valuable component in creating targeted therapies for a range of diseases.
Used in Agrochemical Industry:
In the agrochemical sector, 5-chloro-7-methyl-1H-pyrrolo[3,2-b]pyridine is utilized as a building block for the creation of novel agrochemicals, potentially enhancing crop protection and management strategies through its incorporation into new chemical entities with pesticidal properties.
Used in Materials Science:
5-chloro-7-methyl-1H-pyrrolo[3,2-b]pyridine is employed in materials science as a component in the design and synthesis of advanced materials, leveraging its unique structure to contribute to the development of materials with specific properties for various applications, such as in electronics or nanotechnology.
Used in Organic Chemistry Research:
As a compound of interest in organic chemistry, 5-chloro-7-methyl-1H-pyrrolo[3,2-b]pyridine is used in research to explore its reactivity, synthesis pathways, and potential to form new chemical entities, further expanding the understanding of heterocyclic chemistry and its applications.

InChI:InChI=1S/C8H7ClN2/c1-5-4-7(9)11-6-2-3-10-8(5)6/h2-4,10H,1H3

Upstream product

• 23056-33-9 2-chloro-4-methyl-5-nitro-pyridine 
• 1826-67-1 vinyl magnesium bromide 

Relevant academic research and scientific papers

PESTICIDALLY ACTIVE PYRIDYL- AND PYRIMIDYL- SUBSTITUTED THIAZOLE AND THIADIAZOLE DERIVATIVES

Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as agrochemical active ingredients and can be prepared in a manner known per se.

Inhibitors of HIV-1 attachment. Part 10. the discovery and structure-activity relationships of 4-azaindole cores

A series of 4-azaindole oxoacetic acid piperazine benzamides was synthesized and evaluated in an effort to identify an oral HIV-1 attachment inhibitor with the potential to improve upon the pre-clinical profile of BMS-378806 (7), an initial clinical compound. Modifications at the 7-position of the 4-azaindole core modulated potency significantly and SAR showed that certain compounds with a 5-membered ring heteroaryl group at that position were the most potent. Four of the compounds with the best profiles were evaluated in a rat pharmacokinetic model and all had superior oral bioavailability and lower clearance when compared with 7.

KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS

Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases

KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS

Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases.

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

A general method for the preparation of 4-and 6-azaindoles

Nitropyridines reacted with an excess of vinyl Grignard reagent to produce 4- or 6-azaindoles. Improved yields were obtained when a halogen atom was present at the position α to the nitrogen atom in the pyridine ring.